Astellas dumps a PhIII lung cancer drug; GSK gets one success, one failure in a pair of pivotal Crohn’s trials
→ Japan’s Astellas Pharma is punting its Phase III drug ASP8273, halting the late-stage SOLAR trial evaluating the efficacy and safety of ASP8273 versus erlotinib/gefitinib for the 1st line treatment metastatic or advanced unresectable non-small cell lung cancer harboring sensitizing epidermal growth factor receptor (EGFR) mutation. Astellas says that the decision to scrap the program was made on the recommendation of the independent monitoring board, but didn’t explain what went wrong.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.